All In MedTech

FDA Clearance Tracker · P990081-S035

PATHWAY anti-HER-2/neu (4B5) Rabbit Monoclonal Primary Antibody

A PMA supplement is a change to a device that already has premarket approval, such as a new indication, a design change or a manufacturing change.

Last checked: Nov 20, 2026Latest source record: Mar 13, 2017 (this decision)Source: openFDAMethods & limitations

PMA supplement

The decision

FDA number
P990081-S035
Device name
PATHWAY anti-HER-2/neu (4B5) Rabbit Monoclonal Primary Antibody
Applicant location
Tucson, AZ
Received
Nov 15, 2016
Decided
Mar 13, 2017
Decision
Approved
Supplement type
Normal 180 Day Track
Reason for supplement
Change Design/Components/Specifications/Material
Original approval
P990081

Device type

Device class
Class III

Every decision under product code MVC

FDA's approval statement

As written in FDA's record.

Approval for software modification in the BenchMark XT from NexES to VSS 12.5 and associated hardware changes.

Source documents

Other decisions for Ventana Medical Systems, Inc.

Matched on the applicant name as FDA recorded it. A company that files under several names will have more.

Company page

7 more FDA decisions with a free account

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.